APA (7th ed.) Citation

JR, T., RW, S., SW, M., DV, N., SI, L., BR, N., . . . JM, S. (2001). Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. Journal of medicinal chemistry, 44(21), 3343. https://doi.org/10.1021/jm0155401

Chicago Style (17th ed.) Citation

JR, Tagat, et al. "Piperazine-based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- Methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- Piperidine N1-oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist." Journal of Medicinal Chemistry 44, no. 21 (2001): 3343. https://doi.org/10.1021/jm0155401.

MLA (9th ed.) Citation

JR, Tagat, et al. "Piperazine-based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- Methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- Piperidine N1-oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist." Journal of Medicinal Chemistry, vol. 44, no. 21, 2001, p. 3343, https://doi.org/10.1021/jm0155401.